Metamark Genetics获1000万美元融资用于扩展临床检测产品市场

  最近，Metamark Genetics公司表示，他们已经获得1000万美元融资，用于未来扩展在美国及海外的临床检测产品及服务的市场。
  这笔融资资金将帮助Metamark Genetics完成其它泌尿道检测产品的开发，Metamark宣布Shawn Marcell已经辞去了总裁及CEO的身份去寻找其它的机会了，而后将由公司联合创始人及现任董事会主席Kenneth Weg出任公司CEO一职。
  私人控股公司Metamark位于美国马萨诸塞州的坎布里奇市，其主要开发针对癌症的预后及诊断测试技术，今年早些时候，该公司开发了一种名为ProMark的技术，其可以对前列腺癌的活检组织进行蛋白质组学分类来帮助评估是否早期阶段的前列腺肿瘤是侵袭性的还是缓慢发展型的；这项技术将由Metamark CLIA认证的实验室完成，或将帮助临床医生们确定是否个体癌症需要被积极治疗或监测。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

Metamark Genetics Nabs $10M in Financing
Metamark Genetics today said that it has secured $10 million in financing to further expand its clinical testing products and services in the US and abroad. 

The new funding, the company added, will allow it to complete the development of other urologic assay products. Metamark also announced that Shawn Marcell has resigned as president and CEO of the firm to pursue other opportunities. He has been replaced by Kenneth Weg, a Metamark co-founder and current chairman of the board of directors. 

Privately held Metamark is based in Cambridge, Massachusetts and develops prognostic and diagnostic tests aimed at cancer. Earlier this year, it launched the ProMark, a proteomic classifier of biopsied prostate tissue for assessing whether an early-stage prostate tumor is aggressive or indolent. Performed at Metamark's CLIA-certified laboratory, the test can help a physician decide whether a cancer needs to be treated aggressively or monitored.